Effective May 2nd, GeneDx, formerly a subsidiary of BioReference, has been acquired by Sema4. We’d like to take a moment to reflect on the work that BioReference and GeneDx have accomplished together – helping hundreds of thousands of patients benefit from genomic information to make important health decisions.At BioReference | GenPath, we remain committed to the physician community and patients we serve, and have been working to ensure a smooth transition of comprehensive hereditary cancer and molecular prenatal genetic services. We will continue to offer hereditary cancer testing and prenatal genetic testing, and clients will receive the same level of quality service and experience through BioReference | GenPath.This transaction allows BioReference | GenPath to focus efforts on our three core pillars of digitally-enabled, services-at-scale, and customized healthcare solutions. Additionally, the change will allow us to provide clinically-focused and more streamlined hereditary cancer and prenatal genetic testing solutions.As an evidenced-based and full reference specialty laboratory, BioReference | GenPath is proud to serve clients and is committed to addressing healthcare providers’ laboratory testing needs. We are excited about the forthcoming changes and to continually improve our standards of service. For more information about GenPath Oncology and Comprehensive Hereditary Cancer Services, CLICK HERE For more information about GenPath Women’s Health and Prenatal Genetic Testing, CLICK HERE